References
- Russell IJ. Biochemical Abnormalities in fibromyalgia syn-drome. J Musculoskeletal Pain 1994;2,3:101–15.
- Yunus MB , Dailey JW , Aldag JC , Masi AT , Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: acontrolled study. J Rheumatol 1992;19:90–4.
- Stratz T , Samborski W , Hrycaj P , Pap T , Mackiewicz S , Mennet P , Muller W. Serotoninkonzentration im Serum bei Patienten mit generalisierter Tendomyopathie (Fibromyalgie) und chronischer Polyarthritis. Med Klein 1993;88:458–62.
- Vaeroy H , Helle R , Form 0, Kas E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pan 1988;32: 21–6.
- Russell IJ , Orr MD , Littmann B , Vipraio GA , Albonkrek D , Michalek IE , et al . Elevated cerebro spinal levels of substance P in patients with fibromyalgia syndrome. Arthritis Rheum 1995;37:1593— 1601.
- Inoue A , Hashimoto T , Hide I , Nishio H , Nakata Y. 5-Hydroxytryptamine-facilitated release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP. J Neurochem 1997;68: 128–33.
- Jantunen IT , Kataja VV , Muhonen IT An overview of randomized studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. European Journal of Cancer 1997;33:66–74.
- Russell D , Kenny GN . 5-HT3 antagonists in postoperative nausea and vomiting. British Journal of Anaesthesia 1992;7 Suppl 1:63–8.
- Milner W , Lautenschläger J . Die generalisierte Tendo-myopathie (GTM) Teil I: Klinik, Verlauf und Differential-diagnose. Z Rheumatol 1990;49:11— 21.
- Blackburn TP , Baxter GS , Kennett GA. BRL 46047A: a highly potent, selective, and long-acting 5-HT3 receptor antagonist with anxiolytic-like properties. Psychopharma-cology 1993;110: 257–64.
- Ferrari MD , Wilkinson H , Hirt D , Lataste X , Notter M.Efficacy of ICS 205–930, a novel 5-hydroxytryptamin 3 (5-HT3) receptor antagonist in the prevention of migraine attacks. A complex answer to a simple question. Pain 1991;45: 283–91.
- Wolfe F , Russell U , Vipraio G , Ross K , Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24:555–9.
- Caruso I , Sarzi Puttini P , Cazzola M , Azzolini V . Double blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18:201–9.
- Russell IJ , Orr MD , Vipraio GA , et al . Cerebrospinal fluidsubstance P is elevated in fibromyalgia syndrome. Arthritis Rheum 1992;36:223.
- Spaeth M , Stratz T , Schmalisch P , Fischer P , Haslinger A , Schwarz M , MUller W , Pongratz D . Substance P in skeletal muscle of patients with fibromyalgia syndrome. J Musculo-skeletal Pain 1998;6 Suppl 2:78.
- Saria A , Javorsky F , Humpel C , Gamse R . 5-HT3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990;1:104–6.
- Lee CR , Plosker GL , McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46:925–43.